Difference between revisions of "Part:BBa K4165145"
Line 8: | Line 8: | ||
It is derived from D-enantiomeric peptide, its amino acid sequence is TTSLQMRLYYP. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK. It can penetrate cell membrane and nuclei. | It is derived from D-enantiomeric peptide, its amino acid sequence is TTSLQMRLYYP. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK. It can penetrate cell membrane and nuclei. | ||
− | |||
− | |||
− | |||
− | |||
===Dry Lab=== | ===Dry Lab=== | ||
Line 34: | Line 30: | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
</html> | </html> | ||
+ | |||
+ | |||
+ | |||
+ | <!-- --> | ||
+ | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> | ||
+ | <partinfo>BBa_K4165145 SequenceAndFeatures</partinfo> | ||
Revision as of 13:37, 6 October 2022
TD28 Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
It is derived from D-enantiomeric peptide, its amino acid sequence is TTSLQMRLYYP. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK. It can penetrate cell membrane and nuclei.
Dry Lab
Modeling
modeled by AlphaFold2, Apptest, ITASSER, RosettaFold and TrRosetta, best model obtained from AlphaFold2
Figure 1.: Predicted 3D structure of Synthetic peptide TD28.
Table 1: Quality assessment parameters of TD28 model.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 10
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 10
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 10
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 10
- 1000COMPATIBLE WITH RFC[1000]
References
1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.